Abstract:Eighty‐one low‐risk first cadaveric renal allograft (CD1) recipients have been studied to evaluate an immunosuppressive regime consisting of azathioprine (AZA) [2 mg/kg initially] and cyclosporine A (CSA) [8 mg/kg initially] but without prednisolone in the first instance. All patients were transfused and had less than 50% panel‐reactive antibodies in both peak and current sera. The dose of CSA was tapered to 4 mg/kg at 10 weeks and the AZA to 1 mg/kg at 17 wk. Rejection episodes were treated with 3 × 1 g i.v. boluses of methylprednisolone. After the second episode, or if the first episode was severe, patients were commenced on oral prednisolone at a dose of 30 mg/day reducing to a baseline of 10 mg 12 wk later. Steroid‐unresponsive or histologically severe rejection was treated with OKT3 or ATG. Median follow‐up to the end of March 1989 was 15.5 months (range 3‐33). The 12‐month actuarial patient and graft survivals were 97% and 87% respectively. Four patients died with functioning grafts at 2, 7, and 17 months of infection (3) and at 13 months of myocardial infarction (1). Three grafts were lost to rejection at 4, 7 and 9 months. Four grafts experienced extensive intragraft thromboses in the 1st wk, leading to graft failure in 2, and 1 graft developed major vessel thrombosis at 5 months. Thirty‐eight patients required post‐operative dialysis. Of these, 2 never functioned, 3 diuresed without CSA reduction, 17 functioned after a 50% reduction and 16 functioned after cessation of CSA. Excluding 2 grafts which failed in the first 2 d because of vascular complications, 20 patients (25%) never experienced rejection, 31 (39%) developed their first rejection in the 1st wk, 18 (23%) in wk 2‐4 and 10 (13%) after the 1st month. Fifteen patients required OKT3 or ATG for severe rejection. Fifty‐one patients (65%) received courses of oral steroids of longer than 4 wk, 35 for rejection, 10 after cessation of CSA for toxicity, and 3 after cessation or reduction of AZA for toxicity. Thirteen (37%) of the patients on prednisolone for rejection have had it stopped at between 7 and 25 months without further rejection. Of the 65 patients with functioning grafts who have been followed for more than 6 months, 38 (59%) are taking CSA and AZA alone and 26 (40%) are taking prednisolone either with AZA and CSA (15), with AZA alone (8) or with CSA alone (3). One patient is taking only CSA. There were 30 infections in 28 patients. The most significant of these were 14 CMV (5 associated with OKT3), 1 Torula, 2 wound infection, 3 bacterial septicemia, 1 fungal septicemia, 2 bacterial pneumonia and several episodes of ascending cholangitis in 1 patient. This experience shows that 35% of low‐risk CD1 recipients can be successfully treated with CSA and AZA without prednisolone and that, after 6 months, maintenance immunosuppression can be achieved without long‐term steroids in more than half of the group.

Assessment of Cyclosporine A Withdrawal in Renal Allograft Transplant Recipients

Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study.

Effect of Switch from Cyclosporine to FK506 on Renal Graft Outcome in Patients after Initial Acute Rejection

A Meta-Analysis of Immunosuppression Withdrawal Trials in Renal Transplantation

Clinical Analysis of 2520 Renal Transplantations in One Center

Improved Clinical Outcomes in Chinese Renal Allograft Recipients Receiving Lower Dose Immunosuppressants

Reduced-Dose Cyclosporine with Mycophenolate Mofetil and Prednisone Significantly Improves the Long-Term Glomerular Filtration Rate and Graft Survival

Relationship between cyclophilin A Mrna expression and acute rejection of human graft kidney

Occurrence and influencing factors of cyclosporine A on the kidney injury following allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis

Risk Factors and Treatment of Focal Segmental Glomerulosclerosis Recurrence in Renal Transplantation

Time-dependent Clearance of Cyclosporine in Adult Renal Transplant Recipients: A Population Pharmacokinetic Perspective

Protective Effect of Low Dose Cyclosporine-a on Ischemic-Reperfusional Kidney

Experience with cyclosporine A and azathioprine double therapy in low‐risk recipients of first cadaveric renal allografts

Effect of cyclosporine on renal function in kidney transplant recipients: a 12‐year follow‐up

Cyclosporine Sparing with the Use of Myco- Phenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients

Risk of steroid withdrawal in pediatric renal allograft recipients (a 5‐year follow‐up)

Retrospective study of two-hour post-dose cyclosporine level (C2) monitoring in long term maintenance phase of renal transplant recipients

Conversion from Cyclosporine to Tacrolimus in Patients with Chronic Allograft Nephropathy

Influence of Cyclosporin A on Molecular Expression of Lymphocytes and Relationship with Pathological Changes after Allogenic Heart Transplantation

Incidence, clinical classification and risk factors of cyclosporin A‐induced liver injury in allogeneic haematopoietic stem cell transplant recipients

The comparison of clinical effects and safety of Neoral, New Cyspin, TianKe in renal allograft transplantation